December 17, 2024 - Non-regulatory SynAct Pharma to join J.P. Morgan Healthcare Conference in San Francisco
November 27, 2024 - Non-regulatory SynAct Pharma receives EU trial approval for the Phase 2b ADVANCE study with resomelagon (AP1189)
November 14, 2024 - Non-regulatory SynAct Pharma presents positive clinical data on resomelagon (AP1189) supporting development for the treatment of RA at ACR Convergence
September 23, 2024 - Non-regulatory SynAct initiates the Phase 2b ADVANCE study with resomelagon (AP1189) in the US
September 13, 2024 - Non-regulatory SynAct Pharma to present clinical data on resomelagon (AP1189) at ACR Convergence
August 30, 2024 - Non-regulatory First scientific publication showing treatment potential of a pro-resolving compound in human virus infection
July 1, 2024 - Non-regulatory SynAct initiates filing process for Phase 2b ADVANCE study with resomelagon
February 22, 2024 - Non-regulatory SynAct Pharma announces additional data from the EXPAND P2b clinical trial supporting continued development of the compound in rheumatoid arthritis
January 30, 2024 - Non-regulatory SynAct Pharma expands its Rheumatology Clinical Advisory Board with three new highly experienced advisors
